<DOC>
	<DOC>NCT00422825</DOC>
	<brief_summary>This is a single center, four-treatment, four period, crossover study to evaluate the effect of food on the relative bioavailability of a single dose of imatinib (STI571) given as a 800 mg modified release tablet, MR2 compared to twice-daily doses of 400 mg film-coated imatinib tablets. There will be a 10 day wash out phase between treatments and a 1 week safety period at the end of the study. Each participant will receive all four treatments</brief_summary>
	<brief_title>Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criteria Healthy male or female subjects (postmenopausal women) Able to communicate well with the investigator and comply with the requirements of the study. Exclusion criteria Smokers Subjects using any prescription drug or overthecounter (OTC) medication (including herbal and alternative medication) within 2 weeks prior to dosing. Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. A past medical history or presence of clinically significant ECG abnormalities including: History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated). History of medications predisposing the subjects for GI bleedings/cerebral hemorrhage. Women taking any biphosphonates (Fosomax like drugs) History of being immunocompromised, including a positive HIV test result. A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. Females nursing infants. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Food effect</keyword>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>imatinib</keyword>
	<keyword>STI571</keyword>
	<keyword>modified release formulation of STI571</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Philadelphia Chromosome</keyword>
</DOC>